VRTX

Centessa Pharmaceuticals plc (NASDAQ: CNTA), a clinical-stage biopharmaceutical company, has launched a follow-on public offering of $150 million in American Depositary Shares (ADSs), which represents one ordinary share per ADS. The underwriters for this offering, including prominent financial institutions such as Goldman Sachs, Evercore ISI, and Guggenheim Securities, also have the option to purchase up … Read more